A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes. Skip to main content Open menu Close menu ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone levels.

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes.Now, a clinical trial suggests the medicines can ...